Dong Kim - 09 Sep 2024 Form 4 Insider Report for UroGen Pharma Ltd. (URGN)

Role: Chief Financial Officer
Signature: /s/ Jason D. Smith, Attorney-in-Fact
Issuer symbol: URGN
Transactions as of: 09 Sep 2024
Net transactions value: $0
Form type: 4
Filing time: 12 Sep 2024, 13:50:15 UTC
Previous filing: 02 Feb 2024
Next filing: 27 Mar 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	URGN	Ordinary Shares	Options Exercise		+2,500	+7.1%		37,753	09 Sep 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	URGN	Restricted Stock Units	Options Exercise	$0	-2,500	-33%	$0.000000	5,000	09 Sep 2024	Ordinary Shares	2,500		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.
F2	The reporting person was granted RSUs on September 7, 2023 representing 7,500 ordinary shares. The RSUs will vest in three equal annual installments from September 7, 2024.